Showing results (1431-1440 of 1,447) with videos related to

Sort By:
Pageof 145
Movement Disorders : Official Journal of the Movement Disorder Society|July 28, 2021
A Multi-center Genome-wide Association Study of Cervical DystoniaYan V Sun, Chengchen Li, Qin Hui, et al.
Nature Communications|November 6, 2021
Neoadjuvant T-DM1/pertuzumab and paclitaxel/trastuzumab/pertuzumab for HER2+ breast cancer in the adaptively randomized I-SPY2 trialAmy S Clark, Christina Yau, Denise M Wolf, et al.
NPJ Breast Cancer|December 1, 2022
Safety and efficacy of HSP90 inhibitor ganetespib for neoadjuvant treatment of stage II/III breast cancerJulie E Lang, Andres Forero-Torres, Douglas Yee, et al.
Neurology|December 4, 2016
A randomized, double-blind, placebo-controlled trial of coenzyme Q10 in Huntington diseaseAndrew McGarry, Michael McDermott, Karl Kieburtz, et al.
Nature Medicine|September 14, 2024
Datopotamab-deruxtecan in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trialKatia Khoury, Jane L Meisel, Christina Yau, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|September 17, 2024
Genetic Risk Factors in Isolated Dystonia Escape Genome-Wide Association StudiesBjörn-Hergen Laabs, Katja Lohmann, Eva-Juliane Vollstedt, et al.
NPJ Breast Cancer|October 6, 2021
Ganitumab and metformin plus standard neoadjuvant therapy in stage 2/3 breast cancerDouglas Yee, Claudine Isaacs, Denise M Wolf, et al.
Nature Medicine|September 14, 2024
Datopotamab-deruxtecan plus durvalumab in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trialRebecca A Shatsky, Meghna S Trivedi, Christina Yau, et al.
Journal of Clinical Medicine|November 19, 2020
Safety and Tolerability of SRX246, a Vasopressin 1a Antagonist, in Irritable Huntington's Disease Patients-A Randomized Phase 2 Clinical TrialMichael J Brownstein, Neal G Simon, Jeffrey D Long, et al.
JAMA Oncology|September 16, 2021
Assessment of Residual Cancer Burden and Event-Free Survival in Neoadjuvant Treatment for High-risk Breast Cancer: An Analysis of Data From the I-SPY2 Randomized Clinical TrialW Fraser Symmans, Christina Yau, Yunn-Yi Chen, et al.
Pageof 145